Pharmaceutical Marketing's Contributions to Quality of Life

Journal of Pharmaceutical Marketing and Management

Volumn 14, Issue 42067, 2002, Pages 109-127

  Bentley, John P ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

health related quality of life; Pharmaceutical marketing; quality of life

Indexed keywords

EID: 80054852924     PISSN: 08837597     EISSN: 15408574     Source Type: Journal    
DOI: 10.3109/J058v14n03_08     Document Type: Article

References (37)

1. Merck and Company. About Merck [resource on World Wide Web]. URL: http://www.merck.com/about/. Available from Internet. Accessed 2001 Mar 7.
2. Kotler P. Principles of marketing. 3rd ed. Englewood Cliffs, NJ: Prentice-Hall; 1986.
3. Wilkie WL, Moore ES. Marketing's contributions to society. J Marketing. 1999; 63(Special Issue):198-218. (reprinted in this issue of JPMM on pp. 11 – 56)
4. Sirgy MJ, Meadow HL, Samli AC. Past, present, and future: An overview of quality of life research in marketing. In: New dimensions in marketing/quality of life research. Sirgy MJ, Samli AC, eds. Westport, CT: Quorum Books; 1995: 335 – 64.
5. Patrick DL, Chiang YP. Measurement of health outcomes in treatment effec-tiveness evaluations: Conceptual and methodological challenges. Med Care. 2000; 38 (9 Suppl):II 144125.
6. Glossary: Health outcomes methodology. Med Care. 2000; 38(9 Suppl): 1174113.
7. Morris MH, Sexton DL, Lewis PS. Small business, entrepreneurship, and qual-ity of life: A growth perspective. In: New dimensions in marketing/quality of life re-search. Sirgy MJ, Samli AC, eds. Westport, CT: Quorum Books; 1995: 71 – 94.
8. Sirgy MJ, Lee DJ. Setting socially responsible marketing objectives: A quality of life approach. Eur J Marketing. 1996; 30 (5): 20 – 34.
9. Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the valid-ity of quality of life claims for labeling and promotion. Value in Health. 1999; 2: 113 – 27.
10. Ware JE. The status of health assessment 1994. Aim Rev Public Health. 1995; 16: 327 – 54.
11. Sirgy MJ, Samli AC, eds. New dimensions in marketing/quality of life research. Westport, CT: Quorum Books; 1995.
12. Kotler P. Marketing management: Analysis, planning, implementation, and control. 7th ed. Englewood Cliffs, NJ: Prentice-Hall; 1991.
13. Shaw EH. Book review: New dimensions in marketing/quality of life research. J Macromarketing. 1997; 17: 132 – 5.
14. Schoell WF, Guiltinan JP. Marketing: Contemporary concepts and practices. 4th ed. Boston: Allyn and Bacon; 1990.
15. Morris LA, Beckett TK, Lechter KJ. A marketing perspective: Theoretical un-derpinnings. In: Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Spilker B, ed. Philadelphia: Lippincott-Raven Publishers; 1996: 541 – 8.
16. Revicki DA, Ehreth JL. Health-related quality of life assessment and planning for the pharmaceutical industry. Clin Ther. 1997; 19: 1101 – 15.
17. Burke LB. U.S. regulation of pharmaceutical outcomes research. Value in Health. 2001; 4: 5 – 7.
18. Spilker B, Garbus SB. An industry perspective. In: Quality of life and pharma-coeconomics in clinical trials. 2nd ed. Spilker B, ed. Philadelphia: Lippincott-Raven Publishers; 1996: 535 – 40.
19. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986; 314: 1657 – 64.
20. Jack W. Pharmaceutical differentiation through quality of life measurement: A case study. J Pharm Market Manage. 1991; 6 (1): 65 – 85.
21. Brock D. Quality of life measures in health care and medical ethics. In: Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Spilker B, ed. Philadelphia: Lippincott-Raven Publishers; 1996: 497 – 510.
22. Spilker B. Multinational pharmaceutical companies: Principles and practices. 2nd ed. New York: Raven Press; 1994.
23. McHorney CA. Concepts and measurement of health status and health-related quality of life. In: Handbook of social studies in health and medicine. Albrecht GL, Fitzpatrick R, Scrimshaw SC, eds. Thousand Oaks, CA: SAGE Publications; 2000: 339 – 58.
24. Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996.
25. Staquet MJ, Hays RD, Fayers PM, eds. Quality of life assessment in clinical tri-als: Methods and practice. New York: Oxford University Press; 1998.
26. Lohr KN. Health outcomes methodology symposium: Summary and recom-mendations. Med Care. 2000; 38 (9 Suppl): 11194 – 11208.
27. Bungay KM, Ware JE. Current concepts: Measuring and monitoring health-re-lated quality of life. Kalamazoo, MI: The Upjohn Company; 1993.
28. Merck and Company. Merck corporate philanthropy report [resource on World Wide Web]. URL: http://www.merck.com/overview/philanthropy/. Available from Internet. Accessed 2001 Mar 7.
29. Eli Lilly and Company. Eli Lilly and Company Foundation Web Page [resource on World Wide Web]. URL: http://www.lilly.com/about/community/foundation/ index.html. Available from Internet. Accessed 2001 Mar 7.
30. Manasse HR. Medication use in an imperfect world: Drug misadventuring as an issue of public policy, Part 1. Am J Hosp Pharm. 1989; 46: 929 – 44.
31. Manas se HR. Medication use in an imperfect world: Drug misadventuring as an issue of public policy, Part 2. Am J Hosp Pharm. 1989; 46: 1141 – 52.
32. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47: 533 – 43.
33. Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost-of-ill-ness model. Arch Intern Med. 1995; 155: 1949 – 56.
34. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hos-pitalized patients: A meta-analysis of prospective studies. JAMA. 1998; 279: 1200 – 5.
35. Murawski MM, Bentley JP. Pharmaceutical therapy-related quality of life: Conceptual development. J Soc Admin Pharm. 2001; 18: 2 – 14.
36. Holton MF. Direct-to-consumer marketing of prescription drugs: Creating con-sumer demand. JAMA. 1999; 281: 382 – 4.
37. Angell M. The pharmaceutical industry—to whom is it accountable? N Engl J Med. 2000; 342: 1902 – 4.